A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS
- 12 April 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 64 (7), 1298-1300
- https://doi.org/10.1212/01.wnl.0000156913.24701.72
Abstract
There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.Keywords
This publication has 8 references indexed in Scilit:
- Reversible ALS-like disorder in HIV infectionNeurology, 2001
- An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapyNeurology, 2001
- Detection of reverse transcriptase activity in the serum of patients with motor neurone diseaseJournal of Medical Virology, 2000
- Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis In Vitro and In VivoBlood, 1999
- Improvement in Immune Function due to Treatment with Indinavir despite Severe Immune DeficiencyAntiviral Therapy, 1998
- The Amyotrophic Lateral Sclerosis Functional Rating ScaleArchives of Neurology, 1996
- HTLV tax-rex DNA and antibodies in idiopathic amyotrophic lateral sclerosisJournal of the Neurological Sciences, 1995
- Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological diseaseJournal of Virology, 1994